151 related articles for article (PubMed ID: 11442659)
1. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL.
Yamamoto S; Ito T; Akiyama A; Aizawa T; Miki M; Tachibana M
Int J Urol; 2001 Jul; 8(7):374-9. PubMed ID: 11442659
[TBL] [Abstract][Full Text] [Related]
2. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
Furuya Y; Nagakawa O; Fuse H
Urol Int; 2003; 70(3):195-9. PubMed ID: 12660456
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
Fujikawa K; Matsui Y; Fukuzawa S; Takeuchi H
Eur Urol; 2000 Feb; 37(2):218-22. PubMed ID: 10705202
[TBL] [Abstract][Full Text] [Related]
6. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A
J Urol; 1999 Jan; 161(1):176-81. PubMed ID: 10037393
[TBL] [Abstract][Full Text] [Related]
7. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
8. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
Fujita M; Goto T; Uchida K; Saiki S; Arima R
Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Collette L; de Reijke TM; Schröder FH;
Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
12. [Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications].
Morote J; Vallejo C; Lorente JA; Encabo G; López Pacios MA; de Torres JA; Soler Roselló A
Actas Urol Esp; 1995 Sep; 19(8):604-10. PubMed ID: 8669327
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
14. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer.
Kawakami S; Takagi K; Yonese J; Ueda T; Fukui I; Kawai T
Eur Urol; 1997; 32(1):58-63. PubMed ID: 9266233
[TBL] [Abstract][Full Text] [Related]
16. Metastatic prostate cancer with normal level of serum prostate-specific antigen.
Nishio R; Furuya Y; Nagakawa O; Fuse H
Int Urol Nephrol; 2003; 35(2):189-92. PubMed ID: 15072491
[TBL] [Abstract][Full Text] [Related]
17. Combined finasteride and flutamide therapy in men with advanced prostate cancer.
Ornstein DK; Rao GS; Johnson B; Charlton ET; Andriole GL
Urology; 1996 Dec; 48(6):901-5. PubMed ID: 8973674
[TBL] [Abstract][Full Text] [Related]
18. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
[TBL] [Abstract][Full Text] [Related]
19. Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
Yamamoto S; Yonese J; Kawakami S; Tsukamoto T; Ohkubo Y; Tatokoro M; Fukui I
Int J Clin Oncol; 2006 Aug; 11(4):326-8. PubMed ID: 16937308
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
